Climb Bio Q1 cash $197.8M; pipeline on track for 2025 milestones

Climb Bio, Inc.

Cash and marketable securities $197.8M; expected to fund operations through 2027.
R&D expense $17.3M including $9.0M upfront to Mabworks for CLYM116 license.
Budoprutug Phase 2 pMN FDA-cleared; ITP and SLE trials on track for H1 2025 initiation.
CLYM116 IND/CTA submission expected H2 2025 with preclinical data in H2.
Appointed Kim Drapkin and Bo Cumbo as independent directors; Perrin Wilson as CBO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.